 |
|
ADH-1
A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Exherin | | |
| Previous: | adenovirus encoding human aquaporin-1, adenovirus encoding recombinant human endostatin, adenovirus HER2-transduced autologous dendritic cell vaccine, adenovirus vector, adenovirus-interferon-gamma TG1042 | | Next: | adipose-derived regenerative cells, adozelesin, Adriamycin PFS, Adriamycin RDF, Adrucil |
|
|
